We examined the association between SGLT2 inhibitors use and the risks of MACE and MAKE in several subgroups including age ( ≤ 60 and > 60 years), sex (male and female), race (white and Black), vaccination status (unvaccinated, received 1 or 2 doses of vaccine, boosted), status of hospitalization during acute phase of SARS-CoV-2 infection, metformin use, insulin use, cardiovascular disease status, BMI ( > 30 and ≤ 30 kg/m2) and eGFR ( ≥ 60 and < 60 ml/min/1.73m2). Here, SLC5A2 is linked to cardiovascular disorder.